Harbour BioMed, Insilico Medicine enter strategic collaboration to advance AI-driven antibody discovery and development: Cambridge, Massachusetts Saturday, February 22, 2025, 14:0 ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and ...

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and ...

February 20, 2025, Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their ...

Biomissile Pharmaceuticals Co. Ltd. is developing multispecific antibodies that overcome resistance associated with antibody-drug conjugates via its next-generation natural killer (NK) cell engagers.

Fresh off winning a Nobel Prize last year, and previously tackling antibodies and peptides, the University of Washington’s David Baker and his team aim to make another breakthrough in art | As an ...

This contract involves Da An Biotherapeutics supplying antibodies that LigaChem Biosciences will develop into ADC new drugs. The next-generation cancer treatment core technology, ADC, accurately ...